A prospective trial to evaluate the safety, tolerability and pharmacokinetics of a single intravenous dose of CB-181963 in healthy male subjects

Trial Profile

A prospective trial to evaluate the safety, tolerability and pharmacokinetics of a single intravenous dose of CB-181963 in healthy male subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2010

At a glance

  • Drugs CB 181963 (Primary)
  • Indications Gram-negative infections; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 05 Nov 2010 New trial record.
    • 13 May 2003 According to a Cubist Pharmaceuticals media release, results of this trial were presented at the 13th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID) 2003.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top